FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Advent Life Sciences LLP   2. Issuer Name and Ticker or Trading Symbol Versartis, Inc. [VSAR] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 158 NORTH GOWER STREET 3. Date of Earliest Transaction (Month/Day/Year) 03/26/2014 (Street) LONDON, X0 NW1 2ND 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Filing(Check Applicable Line) ___ Form filed by One Reporting Person _X_ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 03/26/2014   C   1,258,086 A (1) 1,258,086 I See FN (2) Common Stock 03/26/2014   C   489,253 A (1) 1,747,339 I See FN (2) Common Stock 03/26/2014   C   176,813 A (1) 1,924,152 I See FN (2) Common Stock 03/26/2014   C   78,228 A (1) 2,002,380 I See FN (2) Common Stock 03/26/2014   C   154,178 A (1) 2,156,558 I See FN (2) Common Stock 03/26/2014   P   60,000 A $ 21 2,216,558 I See FN (2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants to Purchase Series B Preferred Stock	$ 0.45	03/26/2014		X			506,376	(3)	03/26/2014	Series B Convertible Preferred Stock	506,376	$ 0	0	I	See FN (2)
Series B Convertible Preferred Stock	(1)	03/26/2014		X		506,376		(4)	(4)	Common Stock	44,031	$ 0	14,468,020	I	See FN (2)
Series B Convertible Preferred Stock	(1)	03/26/2014		C			14,468,020	(4)	(4)	Common Stock	1,258,086	$ 0	0	I	See FN (2)
Series C Convertible Preferred Stock	(1)	03/26/2014		C			5,626,413	(4)	(4)	Common Stock	489,253	$ 0	0	I	See FN (2)
Series D-1 Convertible Preferred Stock	(1)	03/26/2014		C			2,033,350	(4)	(4)	Common Stock	176,813	$ 0	0	I	See FN (2)
Series D-2 Convertible Preferred Stock	(1)	03/26/2014		C			899,619	(4)	(4)	Common Stock	78,228	$ 0	0	I	See FN (2)
Series E Convertible Preferred Stock	(1)	03/26/2014		C			1,773,049	(4)	(4)	Common Stock	154,178	$ 0	0	I	See FN (2)

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Advent Life Sciences LLP 158 NORTH GOWER STREET LONDON, X0 NW1 2ND		X
Advent Life Sciences Fund I LP 158 NORTH GOWER STREET LONDON, X0 NW1 2ND		X

Signatures

/s/ Shahzad Malik, General Partner, Advent Life Sciences LLP		03/27/2014
**Signature of Reporting Person		Date
/s/ Shahzad Malik, General Partner of Advent Life Sciences LLP acting in its capcaity as Manager of Advent Life Sciences Fund I LP		03/27/2014
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	In connection with the completion of the Issuer's initial public offering of Common Stock, each share of Series B Convertible Preferred Stock, Series C Convertible Preferred Stock, Series D-1 Convertible Preferred Stock, Series D-2 Convertible Preferred Stock and Series E Convertible Preferred Stock automatically converted into Common Stock on a 1-for-11.5 basis.
(2)	Securities are held by Advent Life Sciences LLP ("Advent") and Advent Life Sciences Fund I LP ("Advent Fund"). Advent is the general partner of Advent Fund.
(3)	Immediately exercisable. In connection with the closing of the Issuer's initial public offering of Common Stock the warrant to purchase Series B Convertible Preferred Stock shall automatically convert into a warrant to purchase Common Stock on a 1-for-11.5 basis if the warrant is not otherwise exercised prior to such closing.
(4)	The securities do not have an expiration date. Each share of Series B, Series C, Series D-1, Series D-2 and Series E Convertible Preferred Stock converted automatically into shares of Common Stock in connection with the closing of the Issuer's initial public offering on March 26, 2014. Prior to its conversion into the Issuer's Common Stock, The Series B, Series C, Series D-1, Series D-2 and Series E Convertible Preferred Stock was convertible at any time at the option of the holder.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.